13 / 20
Page 37
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Nuclear Medicine & Radiation Therapy 2018
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
PET-CT application for adjustment of thyroid cancer
treatment algorithm
Olena Oliinichenko
2
, Firsova M M
1
and Poliakova N I
2
1
P L Shupik National Medical Academy of Postgraduate Education, Ukraine
2
Kyiv Municipal Clinical Oncology Center, Ukraine
Biography
Olena Oliinichenko has studied in Bogomolets National Medical
University, Kyiv and graduated in 2009. She has completed her
Internship in Radiology from Bogomolets National SMedical
University in 2011 and special training courses in Nuclear Med-
icine in P L Shupyk National Medical Academy of Postgraduate
Education (NMAPE) in 2011. She worked as a Radiologist in Ra-
diotherapy department of Kyiv Municipal Clinical Oncology Cen-
tre (2009-2011). She worked as a Nuclear Medicine Physician
until now and currently she holds the position of Head of PET/
CT department in Centre of Nuclear Medicine of Kyiv Municipal
Clinical Oncology Centre. She is aMember of EANM, IASLC. She
has completed several trainings by IAEA. She has published fif-
teen papers in core Ukrainian and several international journals.
elenosol86@gmail.comC
ase-records of 10 patients with an average of 54 years have been analyzed
taking into account the ability of PET/CT to provide information on tumor
biology, its metastases and prognostic factors. Among them nine were females
and one was male. PET/CT was applied to decide on possibility to conduct
primary or repetitive iodine therapy courses. There were two cases of mixed
medullary follicular carcinoma, one case of mixed medullary papillary carcinoma
and one case of follicular papillary carcinoma with medullary lesion. Only one
patient within this group has been approved for repetitive iodine therapy courses
after investigation with PET/CT. Four patients had prolongation suspicion and
resistance to radioactive iodine: two of them with growing level of thyroglobulin
135.3 and 532.0 ng/mL registered during the year and additional new lesions
detected by CT and two with stably elevated level of thyroglobulin 8.4-8.9 ng/L
and 9.3-9.8 ng/L during two years of monitoring. All of them had negative iodine
scans. Investigation has detected high level of standard uptake value (SUV)
from eight to 24 in patients with high level of thyroglobulin. Consequently, iodine
therapy was not planned for these patients. Results of instrumental examinations
proved no foci in patients with stably elevated level of thyroglobulin; additionally
no pathological uptake of 18F-FDG has been registered. In two patients with the
following primary diagnosis: poorly differentiated adenocarcinoma, syndrome
of neck tumor compression and medullary carcinoma with metastatic lesions
of lymph nodes, PET/CT has been applied to detect additional lesions and their
metabolic activity (in lungs and lymph nodes with SUV>9). Outcome of PET/CT
application: the investigation enabled adjustment of treatment algorithm in five
patients and was useful as a prognostic tool in other patients.
Olena Oliinichenko et al., J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-002